HIPEC in ovarian cancer: new evidence supports its use
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.
Menu
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.
PANGAEA ONCOLOGY. ALL RIGHTS RESERVED, 2023.
DESIGNED & PRODUCED BY SOTO BUSINESS PARTNERS